Trial · NCT01229423
Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects
NCT01229423, Phase 4, Completed, Allergan; results first posted 2012-01-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects. Trials, record NCT01229423. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01229423
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects
- NCT number
- NCT01229423
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 62 participants, actual
- Lead sponsor
- Allergan
- Conditions
- Eyelash Hypotrichosis
- Interventions
- bimatoprost 0.03%
- First posted
- 2010-10-27
- Last updated
- 2019-01-29
- Results first posted
- 2012-01-23
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Eyelash Length at Week 20 | Baseline, Week 20 | Change from baseline in eyelash length at Week 20. Measurements made were based on the mean length of the upper left and right eyelashes. A positive change from baseline indicates an increase in eyelash length, and a negative change from baseline indicates a decrease in eyelash length. |
| Secondary | Percentage of Subjects With an Improvement of at Least 1-Point in Global Eyelash Assessment (GEA) Score at Week 20 | Week 20 | Percentage of subjects with an improvement of at least 1-point in GEA score at Week 20 from baseline. The GEA scale is an investigator-graded 4-point scale of overall eyelash prominence where 1=minimal, 2=moderate, 3=marked, and 4=very marked prominence. |
| Secondary | Change From Baseline in Eyelash Thickness at Week 20 | Baseline, Week 20 | Change from baseline in eyelash thickness at Week 20. Assessments made were based on the mean thickness of the upper left and right eyelashes. A positive change from baseline indicates an increase in eyelash thickness, and a negative change from baseline indicates a decrease in eyelash thickness. |
| Secondary | Change From Baseline in Eyelash Intensity (Darkness) at Week 20 | Baseline, Week 20 | Change from baseline in eyelash intensity (darkness) at Week 20. Assessments made were based on the mean eyelash intensity of the upper left and right eyelashes. Intensity was measured on a scale ranging from 0 (black) to 255 (white). A negative change from baseline indicates eyelash darkening in color, and a positive change from baseline indicates eyelash lightening in color. |
| Secondary | Percentage of Subjects With an Improvement in Satisfaction With Overall Eyelash Prominence at Week 20 | Week 20 | Percentage of subjects with an improvement in satisfaction with overall eyelash prominence at Week 20. Subject satisfaction with overall eyelash prominence was assessed by response to the question "Overall how satisfied are you with your eyelashes?" Responses were based on a 5-point scale ("very unsatisfied", "unsatisfied", "neutral", "satisfied", "very satisfied"). Improvement in subject satisfaction is defined as a 1-point increase from baseline. |
| Secondary | Percentage of Subjects Satisfied With Treatment at Week 20 | Week 20 | Percentage of subjects satisfied with treatment at week 20 was assessed using the Treatment Satisfaction Scale response to the question "Which best describes your satisfaction with LATISSE®?" Responses were "very satisfied", "satisfied", "neutral", "unsatisfied", and "very unsatisfied." Satisfied is defined as responses of "very satisfied" and "satisfied." |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Eyelash Length at Week 20 | Baseline, Week 20 | Intent-to-Treat (ITT) included all patients enrolled in the trial who received at least one application of study drug. | Millimeter (mm) | MEAN |
| SECONDARY | Percentage of Subjects With an Improvement of at Least 1-Point in Global Eyelash Assessment (GEA) Score at Week 20 | Week 20 | Intent-to-Treat (ITT) included all patients enrolled in the trial who received at least one application of study drug. | Percentage of Subjects | NUMBER |
| SECONDARY | Change From Baseline in Eyelash Thickness at Week 20 | Baseline, Week 20 | Intent-to-Treat (ITT) included all patients enrolled in the trial who received at least one application of study drug. | Millimeters Squared (mm^2) | MEAN |
| SECONDARY | Change From Baseline in Eyelash Intensity (Darkness) at Week 20 | Baseline, Week 20 | Intent-to-Treat (ITT) included all patients enrolled in the trial who received at least one application of study drug. | Units on a Scale | MEAN |
| SECONDARY | Percentage of Subjects With an Improvement in Satisfaction With Overall Eyelash Prominence at Week 20 | Week 20 | Intent-to-Treat (ITT) included all patients enrolled in the trial who received at least one application of study drug. | Percentage of Subjects | NUMBER |
| SECONDARY | Percentage of Subjects Satisfied With Treatment at Week 20 | Week 20 | Intent-to-Treat (ITT) included all patients enrolled in the trial who received at least one application of study drug. | Percentage of Subjects | NUMBER |
Source ClinicalTrials.gov
Results by group9
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Eyelash Length at Week 20 | LATISSE® | Baseline | 5.92 | Standard Deviation 0.72 | Millimeter (mm) |
| Change From Baseline in Eyelash Length at Week 20 | LATISSE® | Change from Baseline at Week 20 | 1.10 | Standard Deviation 0.8 | Millimeter (mm) |
| Percentage of Subjects With an Improvement of at Least 1-Point in Global Eyelash Assessment (GEA) Score at Week 20 | LATISSE® | 81.4 | Percentage of Subjects | ||
| Change From Baseline in Eyelash Thickness at Week 20 | LATISSE® | Baseline | 1.39 | Standard Deviation 0.395 | Millimeters Squared (mm^2) |
| Change From Baseline in Eyelash Thickness at Week 20 | LATISSE® | Change from Baseline at Week 20 | 0.25 | Standard Deviation 0.269 | Millimeters Squared (mm^2) |
| Change From Baseline in Eyelash Intensity (Darkness) at Week 20 | LATISSE® | Baseline | 140.02 | Standard Deviation 15.788 | Units on a Scale |
| Change From Baseline in Eyelash Intensity (Darkness) at Week 20 | LATISSE® | Change from Baseline at Week 20 | -12.97 | Standard Deviation 13.115 | Units on a Scale |
| Percentage of Subjects With an Improvement in Satisfaction With Overall Eyelash Prominence at Week 20 | LATISSE® | 83.05 | Percentage of Subjects | ||
| Percentage of Subjects Satisfied With Treatment at Week 20 | LATISSE® | 83.1 | Percentage of Subjects |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | LATISSE® | 62 | |
| Overall Study | COMPLETED | LATISSE® | 47 | |
| Overall Study | NOT COMPLETED | LATISSE® | 15 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Conjunctival Hyperaemia | Eye disorders | LATISSE® | 6 | 62 | |
| other | Nasopharyngitis | Infections and infestations | LATISSE® | 9 | 62 | |
| other | Hypertrichosis | Skin and subcutaneous tissue disorders | LATISSE® | 4 | 62 | |
| other | Skin Hyperpigmentation (eyelid) | Skin and subcutaneous tissue disorders | LATISSE® | 8 | 62 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | LATISSE® | ||
| Total, other adverse events | LATISSE® | 27 | 62 |
| Total, serious adverse events | LATISSE® | 0 | 62 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 25228046 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01229423
GET https://conductscience.org/api/trials/v1/NCT01229423/registered